Hmdb loader

Showing Protein Fusion glycoprotein F0 (HMDBP14050)

IdentificationBiological propertiesGene propertiesProtein propertiesExternal linksReferencesXMLShow 0 metabolites
Identification
HMDB Protein ID HMDBP14050
Secondary Accession Numbers None
Name Fusion glycoprotein F0
Synonyms Not Available
Gene Name F
Protein Type Unknown
Biological Properties
General Function Not Available
Specific Function Inactive precursor that is cleaved at two sites by a furin-like protease to give rise to the mature F1 and F2 fusion glycoproteins.Class I viral fusion protein (PubMed:23618766). Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state (PubMed:23618766). During viral and plasma cell membrane fusion, the coiled coil regions assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain (PubMed:23618766, PubMed:19966279). The formation of this structure appears to drive apposition and subsequent fusion of viral and cellular membranes leading to delivery of the nucleocapsid into the cytoplasm (PubMed:23593008, PubMed:23618766). This fusion is pH independent and occurs at the plasma or endosomal membrane (Probable). The trimer of F1-F2 (F protein) also facilitates the attachment to host cell by binding to host heparan sulfate (PubMed:10864656). F protein is involved in the entry into the host cell through the interaction with host IGFR1 (PubMed:32494007). This interaction activates PRKCZ/PKCzeta that recruits host NCL/nucleolin to the apical cell surface where it can bind fusion glycoprotein F1 (PubMed:32494007, PubMed:21841784). Later in infection, F protein expressed at the plasma membrane of infected cells can mediate fusion with adjacent cells to form syncytia, a cytopathic effect that could lead to tissue necrosis (PubMed:10438814). F protein may trigger p53-dependent apoptosis (PubMed:18216092).Major determinant of the species specificity of RSV infection (PubMed:12663767). The trimer of F1-F2 (F protein) also facilitates the attachment to host cell by binding to host heparan sulfate (PubMed:10864656). F protein is involved in the entry into the host cell through the interaction with host IGFR1 (PubMed:32494007). This interaction activates PRKCZ/PKCzeta that recruits host NCL/nucleolin to the apical cell surface where it can bind fusion glycoprotein F1 (PubMed:32494007). Later in infection, F protein expressed at the plasma membrane of infected cells can mediate fusion with adjacent cells to form syncytia, a cytopathic effect that could lead to tissue necrosis (PubMed:10438814). F protein seems to trigger p53-dependent apoptosis (PubMed:18216092).
Pathways Not Available
Reactions Not Available
GO Classification
Biological Process
viral entry into host cell via membrane fusion with the plasma membrane
entry receptor-mediated virion attachment to host cell
positive regulation of syncytium formation by virus
Cellular Component
integral to membrane
viral envelope
host cell plasma membrane
host cell Golgi membrane
virion membrane
Molecular Function
identical protein binding
Cellular Location Not Available
Gene Properties
Chromosome Location Not Available
Locus Not Available
SNPs Not Available
Gene Sequence Not Available
Protein Properties
Number of Residues Not Available
Molecular Weight 63452.745
Theoretical pI Not Available
Pfam Domain Function
Signals
  • 1-25;
Transmembrane Regions
  • 525-550;
Protein Sequence Not Available
GenBank ID Protein Not Available
UniProtKB/Swiss-Prot ID P03420
UniProtKB/Swiss-Prot Entry Name FUS_HRSVA
PDB IDs
GenBank Gene ID Not Available
GeneCard ID Not Available
GenAtlas ID Not Available
HGNC ID Not Available
References
General References
  1. Pastey MK, Crowe JE Jr, Graham BS: RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. J Virol. 1999 Sep;73(9):7262-70. [PubMed:10438814 ]
  2. Connors M, Crowe JE Jr, Firestone CY, Murphy BR, Collins PL: A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology. 1995 Apr 20;208(2):478-84. [PubMed:7747420 ]
  3. Crowe JE Jr, Firestone CY, Whitehead SS, Collins PL, Murphy BR: Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes. 1996;13(3):269-73. [PubMed:9035372 ]
  4. Firestone CY, Whitehead SS, Collins PL, Murphy BR, Crowe JE Jr: Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology. 1996 Nov 15;225(2):419-22. [PubMed:8918930 ]
  5. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR: Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol. 1998 May;72(5):4467-71. [PubMed:9557743 ]
  6. Collins PL, Huang YT, Wertz GW: Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. Proc Natl Acad Sci U S A. 1984 Dec;81(24):7683-7. doi: 10.1073/pnas.81.24.7683. [PubMed:6096849 ]
  7. Gonzalez-Reyes L, Ruiz-Arguello MB, Garcia-Barreno B, Calder L, Lopez JA, Albar JP, Skehel JJ, Wiley DC, Melero JA: Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9859-64. doi: 10.1073/pnas.151098198. Epub 2001 Aug 7. [PubMed:11493675 ]
  8. Arumugham RG, Seid RC Jr, Doyle S, Hildreth SW, Paradiso PR: Fatty acid acylation of the fusion glycoprotein of human respiratory syncytial virus. J Biol Chem. 1989 Jun 25;264(18):10339-42. [PubMed:2732224 ]
  9. Feldman SA, Audet S, Beeler JA: The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol. 2000 Jul;74(14):6442-7. doi: 10.1128/jvi.74.14.6442-6447.2000. [PubMed:10864656 ]
  10. Sugrue RJ, Brown C, Brown G, Aitken J, McL Rixon HW: Furin cleavage of the respiratory syncytial virus fusion protein is not a requirement for its transport to the surface of virus-infected cells. J Gen Virol. 2001 Jun;82(Pt 6):1375-1386. doi: 10.1099/0022-1317-82-6-1375. [PubMed:11369882 ]
  11. Zimmer G, Budz L, Herrler G: Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences. J Biol Chem. 2001 Aug 24;276(34):31642-50. doi: 10.1074/jbc.M102633200. Epub 2001 Jun 19. [PubMed:11418598 ]
  12. Begona Ruiz-Arguello M, Gonzalez-Reyes L, Calder LJ, Palomo C, Martin D, Saiz MJ, Garcia-Barreno B, Skehel JJ, Melero JA: Effect of proteolytic processing at two distinct sites on shape and aggregation of an anchorless fusion protein of human respiratory syncytial virus and fate of the intervening segment. Virology. 2002 Jul 5;298(2):317-26. doi: 10.1006/viro.2002.1497. [PubMed:12127793 ]
  13. Schlender J, Zimmer G, Herrler G, Conzelmann KK: Respiratory syncytial virus (RSV) fusion protein subunit F2, not attachment protein G, determines the specificity of RSV infection. J Virol. 2003 Apr;77(8):4609-16. doi: 10.1128/jvi.77.8.4609-4616.2003. [PubMed:12663767 ]
  14. Brock SC, Heck JM, McGraw PA, Crowe JE Jr: The transmembrane domain of the respiratory syncytial virus F protein is an orientation-independent apical plasma membrane sorting sequence. J Virol. 2005 Oct;79(19):12528-35. doi: 10.1128/JVI.79.19.12528-12535.2005. [PubMed:16160180 ]
  15. Day ND, Branigan PJ, Liu C, Gutshall LL, Luo J, Melero JA, Sarisky RT, Del Vecchio AM: Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function. Virol J. 2006 May 24;3:34. doi: 10.1186/1743-422X-3-34. [PubMed:16723026 ]
  16. Eckardt-Michel J, Lorek M, Baxmann D, Grunwald T, Keil GM, Zimmer G: The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis. J Virol. 2008 Apr;82(7):3236-49. doi: 10.1128/JVI.01887-07. Epub 2008 Jan 23. [PubMed:18216092 ]
  17. Low KW, Tan T, Ng K, Tan BH, Sugrue RJ: The RSV F and G glycoproteins interact to form a complex on the surface of infected cells. Biochem Biophys Res Commun. 2008 Feb 8;366(2):308-13. doi: 10.1016/j.bbrc.2007.11.042. Epub 2007 Nov 26. [PubMed:18036342 ]
  18. Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG: Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med. 2011 Aug 14;17(9):1132-5. doi: 10.1038/nm.2444. [PubMed:21841784 ]
  19. McLellan JS, Ray WC, Peeples ME: Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol. 2013;372:83-104. doi: 10.1007/978-3-642-38919-1_4. [PubMed:24362685 ]
  20. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ: Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11133-8. doi: 10.1073/pnas.1309070110. Epub 2013 Jun 17. [PubMed:23776214 ]
  21. Krzyzaniak MA, Zumstein MT, Gerez JA, Picotti P, Helenius A: Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 2013;9(4):e1003309. doi: 10.1371/journal.ppat.1003309. Epub 2013 Apr 11. [PubMed:23593008 ]
  22. Bermingham IM, Chappell KJ, Watterson D, Young PR: The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion. J Virol. 2018 Jan 30;92(4). pii: JVI.01323-17. doi: 10.1128/JVI.01323-17. Print 2018 Feb 15. [PubMed:29212939 ]
  23. Battles MB, McLellan JS: Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019 Apr;17(4):233-245. doi: 10.1038/s41579-019-0149-x. [PubMed:30723301 ]
  24. Griffiths CD, Bilawchuk LM, McDonough JE, Jamieson KC, Elawar F, Cen Y, Duan W, Lin C, Song H, Casanova JL, Ogg S, Jensen LD, Thienpont B, Kumar A, Hobman TC, Proud D, Moraes TJ, Marchant DJ: IGF1R is an entry receptor for respiratory syncytial virus. Nature. 2020 Jul;583(7817):615-619. doi: 10.1038/s41586-020-2369-7. Epub 2020 Jun 3. [PubMed:32494007 ]
  25. Roymans D, De Bondt HL, Arnoult E, Geluykens P, Gevers T, Van Ginderen M, Verheyen N, Kim H, Willebrords R, Bonfanti JF, Bruinzeel W, Cummings MD, van Vlijmen H, Andries K: Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):308-13. doi: 10.1073/pnas.0910108106. Epub 2009 Dec 4. [PubMed:19966279 ]
  26. McLellan JS, Yang Y, Graham BS, Kwong PD: Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011 Aug;85(15):7788-96. doi: 10.1128/JVI.00555-11. Epub 2011 May 25. [PubMed:21613394 ]
  27. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A: Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9619-24. doi: 10.1073/pnas.1106536108. Epub 2011 May 17. [PubMed:21586636 ]
  28. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD: Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013 Nov 1;342(6158):592-8. doi: 10.1126/science.1243283. [PubMed:24179220 ]
  29. Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJM, Widjojoatmodjo MN, Zahn R, Schuitemaker H, McLellan JS, Langedijk JPM: A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015 Sep 3;6:8143. doi: 10.1038/ncomms9143. [PubMed:26333350 ]
  30. Battles MB, Langedijk JP, Furmanova-Hollenstein P, Chaiwatpongsakorn S, Costello HM, Kwanten L, Vranckx L, Vink P, Jaensch S, Jonckers TH, Koul A, Arnoult E, Peeples ME, Roymans D, McLellan JS: Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol. 2016 Feb;12(2):87-93. doi: 10.1038/nchembio.1982. Epub 2015 Dec 7. [PubMed:26641933 ]
  31. Joyce MG, Zhang B, Ou L, Chen M, Chuang GY, Druz A, Kong WP, Lai YT, Rundlet EJ, Tsybovsky Y, Yang Y, Georgiev IS, Guttman M, Lees CR, Pancera M, Sastry M, Soto C, Stewart-Jones GBE, Thomas PV, Van Galen JG, Baxa U, Lee KK, Mascola JR, Graham BS, Kwong PD: Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol. 2016 Sep;23(9):811-820. doi: 10.1038/nsmb.3267. Epub 2016 Aug 1. [PubMed:27478931 ]
  32. Wen X, Mousa JJ, Bates JT, Lamb RA, Crowe JE Jr, Jardetzky TS: Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat Microbiol. 2017 Jan 30;2:16272. doi: 10.1038/nmicrobiol.2016.272. [PubMed:28134915 ]
  33. Rossey I, Gilman MS, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun. 2017 Feb 13;8:14158. doi: 10.1038/ncomms14158. [PubMed:28194013 ]
  34. Roymans D, Alnajjar SS, Battles MB, Sitthicharoenchai P, Furmanova-Hollenstein P, Rigaux P, Berg JVD, Kwanten L, Ginderen MV, Verheyen N, Vranckx L, Jaensch S, Arnoult E, Voorzaat R, Gallup JM, Larios-Mora A, Crabbe M, Huntjens D, Raboisson P, Langedijk JP, Ackermann MR, McLellan JS, Vendeville S, Koul A: Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun. 2017 Aug 1;8(1):167. doi: 10.1038/s41467-017-00170-x. [PubMed:28761099 ]
  35. Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, Wrapp D, Patel NK, Cook KE, Richter BWM, Ryan PC, Yuan AQ, Suzich JA: A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017 May 3;9(388). pii: 9/388/eaaj1928. doi: 10.1126/scitranslmed.aaj1928. [PubMed:28469033 ]
  36. Goodwin E, Gilman MSA, Wrapp D, Chen M, Ngwuta JO, Moin SM, Bai P, Sivasubramanian A, Connor RI, Wright PF, Graham BS, McLellan JS, Walker LM: Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation. Immunity. 2018 Feb 20;48(2):339-349.e5. doi: 10.1016/j.immuni.2018.01.005. Epub 2018 Feb 3. [PubMed:29396163 ]
  37. Outlaw VK, Bottom-Tanzer S, Kreitler DF, Gellman SH, Porotto M, Moscona A: Dual Inhibition of Human Parainfluenza Type 3 and Respiratory Syncytial Virus Infectivity with a Single Agent. J Am Chem Soc. 2019 Aug 14;141(32):12648-12656. doi: 10.1021/jacs.9b04615. Epub 2019 Aug 5. [PubMed:31268705 ]
  38. Gilman MSA, Furmanova-Hollenstein P, Pascual G, B van 't Wout A, Langedijk JPM, McLellan JS: Transient opening of trimeric prefusion RSV F proteins. Nat Commun. 2019 May 8;10(1):2105. doi: 10.1038/s41467-019-09807-5. [PubMed:31068578 ]
  39. Xie Q, Wang Z, Ni F, Chen X, Ma J, Patel N, Lu H, Liu Y, Tian JH, Flyer D, Massare MJ, Ellingsworth L, Glenn G, Smith G, Wang Q: Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein. PLoS One. 2019 Feb 7;14(2):e0210749. doi: 10.1371/journal.pone.0210749. eCollection 2019. [PubMed:30730999 ]
  40. Jones HG, Battles MB, Lin CC, Bianchi S, Corti D, McLellan JS: Alternative conformations of a major antigenic site on RSV F. PLoS Pathog. 2019 Jul 15;15(7):e1007944. doi: 10.1371/journal.ppat.1007944. eCollection 2019 Jul. [PubMed:31306469 ]